Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn

Table of Contents

June 01, 2021; Volume 377,Issue 3

Behavioral Pharmacology

  • You have access
    Novel Antimuscarinic Antidepressant-like Compounds with Reduced Effects on Cognition
    Chad R. Johnson, Brian D. Kangas, Emily M. Jutkiewicz, Gail Winger, Jack Bergman, Andrew Coop and James H. Woods
    Journal of Pharmacology and Experimental Therapeutics June 2021, 377 (3) 336-345; DOI: https://doi.org/10.1124/jpet.120.000337

Cardiovascular

  • You have access
    Chronic Ca2+/Calmodulin-Dependent Protein Kinase II Inhibition Rescues Advanced Heart Failure
    Yixi Liu, Qun Shao, Heng-Jie Cheng, Tiankai Li, Xiaowei Zhang, Michael F. Callahan, David Herrington, Dalane Kitzman, David Zhao and Che-Ping Cheng
    Journal of Pharmacology and Experimental Therapeutics June 2021, 377 (3) 316-325; DOI: https://doi.org/10.1124/jpet.120.000361
  • Open Access
    Therapeutic Assessment of Combination Therapy with a Neprilysin Inhibitor and Angiotensin Type 1 Receptor Antagonist on Angiotensin II–Induced Atherosclerosis, Abdominal Aortic Aneurysms, and Hypertension
    Yasir Alsiraj, Sean E. Thatcher, Ching Ling Liang, Heba Ali, Mark Ensor and Lisa A. Cassis
    Journal of Pharmacology and Experimental Therapeutics June 2021, 377 (3) 326-335; DOI: https://doi.org/10.1124/jpet.121.000525

Cellular and Molecular

  • You have access
    circ-Keratin 6c Promotes Malignant Progression and Immune Evasion of Colorectal Cancer through microRNA-485-3p/Programmed Cell Death Receptor Ligand 1 Axis
    Zhipeng Jiang, Zehui Hou, Wei Liu, Zhuomin Yu, Zhiqiang Liang and Shuang Chen
    Journal of Pharmacology and Experimental Therapeutics June 2021, 377 (3) 358-367; DOI: https://doi.org/10.1124/jpet.121.000518
  • You have access
    Poly(ADP-Ribose) Polymerase Inhibitors for Arsenic Trioxide–Resistant Acute Promyelocytic Leukemia: Synergistic In Vitro Antitumor Effects with Hypomethylating Agents or High-Dose Vitamin C
    Manuela Giansanti, Antonio De Gabrieli, Salvatore Pasquale Prete, Tiziana Ottone, Maria Domenica Divona, Terry Karimi, Fabio Ciccarone, Maria Teresa Voso, Grazia Graziani and Isabella Faraoni
    Journal of Pharmacology and Experimental Therapeutics June 2021, 377 (3) 385-397; DOI: https://doi.org/10.1124/jpet.121.000537

Chemotherapy, Antibiotics, and Gene Therapy

  • Synergistic Pharmacodynamic Effects of Gemcitabine and Fibroblast Growth Factor Receptor Inhibitors on Pancreatic Cancer Cell Cycle Kinetics and Proliferation
    You have access
    Synergistic Pharmacodynamic Effects of Gemcitabine and Fibroblast Growth Factor Receptor Inhibitors on Pancreatic Cancer Cell Cycle Kinetics and Proliferation
    Qingxiang Lin, Zhicheng Qian, William J. Jusko, Donald E. Mager, Wen Wee Ma and Robert M. Straubinger
    Journal of Pharmacology and Experimental Therapeutics June 2021, 377 (3) 370-384; DOI: https://doi.org/10.1124/jpet.120.000412

Drug Discovery and Translational Medicine

  • A Novel Integrated Pharmacokinetic-Pharmacodynamic Model to Evaluate Combination Therapy and Determine <em>In Vivo </em>Synergism
    Open Access
    A Novel Integrated Pharmacokinetic-Pharmacodynamic Model to Evaluate Combination Therapy and Determine In Vivo Synergism
    Young Hee Choi, Chao Zhang, Zhenzhen Liu, Mei-Juan Tu, Ai-Xi Yu and Ai-Ming Yu
    Journal of Pharmacology and Experimental Therapeutics June 2021, 377 (3) 305-315; DOI: https://doi.org/10.1124/jpet.121.000584
  • Open Access
    AM833 Is a Novel Agonist of Calcitonin Family G Protein–Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists
    Madeleine M. Fletcher, Peter Keov, Tin T. Truong, Grace Mennen, Caroline A. Hick, Peishen Zhao, Sebastian G.B. Furness, Thomas Kruse, Trine R. Clausen, Denise Wootten and Patrick M. Sexton
    Journal of Pharmacology and Experimental Therapeutics June 2021, 377 (3) 417-440; DOI: https://doi.org/10.1124/jpet.121.000567

Endocrine and Diabetes

  • You have access
    Ginsenoside Ro Ameliorates High-Fat Diet–Induced Obesity and Insulin Resistance in Mice via Activation of the G Protein–Coupled Bile Acid Receptor 5 Pathway
    Lin-shan Jiang, Wei Li, Tong-xi Zhuang, Jie-jing Yu, Shuai Sun, Zheng-cai Ju, Zheng-tao Wang, Li-li Ding and Li Yang
    Journal of Pharmacology and Experimental Therapeutics June 2021, 377 (3) 441-451; DOI: https://doi.org/10.1124/jpet.120.000435

Gastrointestinal, Hepatic, Pulmonary, and Renal

  • Characterization of Novel Fluorescent Bile Salt Derivatives for Studying Human Bile Salt and Organic Anion Transporters
    Open Access
    Characterization of Novel Fluorescent Bile Salt Derivatives for Studying Human Bile Salt and Organic Anion Transporters
    Michele Leuenberger, Stephanie Häusler, Vera Höhn, Adriana Euler, Bruno Stieger and Martin Lochner
    Journal of Pharmacology and Experimental Therapeutics June 2021, 377 (3) 346-357; DOI: https://doi.org/10.1124/jpet.120.000449

Neuropharmacology

  • You have access
    Brain Concentrations of Methylone and Its Metabolites after Systemic Methylone Administration: Relationship to Pharmacodynamic Effects
    Nicole Centazzo, Michael R. Chojnacki, Joshua S. Elmore, Raider Rodriguez, Teeshavi Acosta, Masaki Suzuki, Kenner C. Rice, Michael H. Baumann and Marta Concheiro
    Journal of Pharmacology and Experimental Therapeutics June 2021, 377 (3) 398-406; DOI: https://doi.org/10.1124/jpet.121.000531
  • You have access
    Development of CVN424: A Selective and Novel GPR6 Inverse Agonist Effective in Models of Parkinson Disease
    Nicola L. Brice, Hans H. Schiffer, Holger Monenschein, Victoria J. Mulligan, Keith Page, Justin Powell, Xiao Xu, Toni Cheung, J. Russell Burley, Huikai Sun, Louise Dickson, Sean T. Murphy, Nidhi Kaushal, Steve Sheardown, Jason Lawrence, Yun Chen, Darian Bartkowski, Anne Kanta, Joseph Russo, Natalie Hosea, Lee A. Dawson, Stephen H. Hitchcock and Mark B. Carlton
    Journal of Pharmacology and Experimental Therapeutics June 2021, 377 (3) 407-416; DOI: https://doi.org/10.1124/jpet.120.000438

Letter to the Editor

  • You have access
    Comments on “Pharmacological Characterization of Apraglutide a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist for the Treatment of Short Bowel Syndrome”
    Jolanta Skarbaliene, Bjarne Due Larsen, Mark Berner-Hansen and Adam Steensberg
    Journal of Pharmacology and Experimental Therapeutics June 2021, 377 (3) 369; DOI: https://doi.org/10.1124/jpet.120.000426

Erratum

  • You have access
    Correction to “Pharmacological Characterization of Apraglutide, a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist, for the Treatment of Short Bowel Syndrome”
    Journal of Pharmacology and Experimental Therapeutics June 2021, 377 (3) 368; DOI: https://doi.org/10.1124/jpet.119.262238err
Back to top
PreviousNext

In this issue

Journal of Pharmacology and Experimental Therapeutics: 377 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 377, Issue 3
1 Jun 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts

Jump to

  • Behavioral Pharmacology
  • Cardiovascular
  • Cellular and Molecular
  • Chemotherapy, Antibiotics, and Gene Therapy
  • Drug Discovery and Translational Medicine
  • Endocrine and Diabetes
  • Gastrointestinal, Hepatic, Pulmonary, and Renal
  • Neuropharmacology
  • Letter to the Editor
  • Erratum
  • Most Read
Loading
  • Potential Clinical Uses of CBG
  • Ocular Drug Delivery: Past, Present, and Future
  • Rho GTPase–Pathway Inhibitor Reduces Markers of Fibrosis
  • Nose-to-Brain Delivery
  • Stem Cells Therapies in AD
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics